RALEIGH, N.C. — Micell Technologies will work with a Boston firm to further develop a manufacturing process for its drug-eluting coatings technology.
Micell contracted with Foster-Miller to initially develop and automate processes needed for the coating of stents used in cardiovascular procedures. Micell said it is looking to develop a manufacturing process to improve efficiency and product performance.
“Foster-Miller has a substantial history of innovation,” said Arthur Benvenuto, Micell’s chairman and chief executive officer. “In addition to their broad experience in developing automated manufacturing systems for the biomedical industry, Foster-Miller has a demonstrated ability to engineer breakthrough concepts that target major markets.”